Inventor · disambiguated record
Rienk Offringa
Also filed as: OFFRINGA RIENK
14 granted patents·21 pending applications·40 citations·filing 2000–2022
89Inventor score
Files withBAYER AG11ACADEMISCH ZIEKENHUIS LEIDEN4UNIV LEIDEN MEDICAL CT3Bayer Pharma AG2DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS2
Top patents by PatentIndex Score
35 records- 0188US11998539B2Substituted aminoquinolones as DGKalpha inhibitors for immune activationBAYER AG·Filed 2022·Granted Jun 4, 2024·1 cites·24 claims
- 0283US7807369B2Methods and means for the treatment of HPV induced intraepithelial neoplasiaUNIV LEIDEN MEDICAL CT·Filed 2006·Granted Oct 5, 2010·10 cites·11 claims
- 0377US7202034B2Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responsesACADEMISCH ZIEKENHUIS LEIDEN·Filed 2001·Granted Apr 10, 2007·12 cites·16 claims
- 0475US11964953B2Substituted aminothiazoles as DGKzeta inhibitors for immune activationBAYER AG·Filed 2022·Granted Apr 23, 2024·0 cites·26 claims
- 0574US7892828B2Method of identifying a MHC class I restricted T cell responseTRANSGENE SA·Filed 2009·Granted Feb 22, 2011·3 cites·3 claims
- 0672US7563445B2CD40 binding molecules and CTL peptides for treating tumorsUNIV HOSPITAL LEIDEN·Filed 2002·Granted Jul 21, 2009·8 cites·15 claims
- 0769US9650423B2Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responsesACADEMISCH ZIEKENHUIS LEIDEN·Filed 2015·Granted May 16, 2017·1 cites·10 claims
- 0868US11427578B1Substituted pyrrolopyridine-derivativesBayer Pharma AG·Filed 2018·Granted Aug 30, 2022·1 cites·18 claims
- 0966US2024327911A1Antigen reactive t-cell receptorsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Application pending·0 cites
- 1065US7560105B1Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responsesLEIDS UNI MEDISCH CT·Filed 2000·Granted Jul 14, 2009·4 cites·43 claims
- 1162US8663646B2P53 peptide vaccineVAN DER BURG SJOERD HENRICUS·Filed 2009·Granted Mar 4, 2014·0 cites·5 claims
- 1262US2023167078A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 1360US2023167103A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 1457US12478621B2Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Granted Nov 25, 2025·0 cites·17 claims
- 1557US10253073B2Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responsesACADEMISCH ZIEKENHUIS LEIDEN·Filed 2017·Granted Apr 9, 2019·0 cites·9 claims
- 1654US2024368280A1Anti-cecam6 antibodies with reduced side-effectsDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2022·Application pending·0 cites
- 1754US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 1854US2015010586A1p53 Peptide VaccineACADEMISCH ZIEKENHUIS LEIDEN·Filed 2014·Application pending·0 cites
- 1953US2009285814A1CD 40 Binding Molecules and CTL Pepetides for Treating TumorsUNIV HOSPITAL LEIDEN·Filed 2009·Application pending·0 cites
- 2051US9115185B2Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responsesVAN DER BURG SJOERD HENDRIKUS·Filed 2007·Granted Aug 25, 2015·0 cites·9 claims
- 2151US2008227082A1Method of identifying a mhc class i restricted t cell responseTRANSGENE SA·Filed 2008·Application pending·0 cites
- 2250US12221479B2Pharmaceutical combination of anti CEACAM6 and TIM3 antibodiesBAYER AG·Filed 2019·Granted Feb 11, 2025·0 cites·11 claims
- 2350US2023064809A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
- 2448US2023062100A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
- 2548US2005255106A1Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40DIEHL LINDA·Filed 2003·Application pending·0 cites
- 2646US2005142640A1MUC-1 derived peptidesIMP CANCER RES TECH·Filed 2005·Application pending·0 cites
- 2745US2022010017A1Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancerBAYER AG·Filed 2019·Application pending·0 cites
- 2845US2011008287A1Methods and means for the treatment of hpv induced intraepithelial neoplasiasUNIV LEIDEN MEDICAL CT·Filed 2010·Application pending·0 cites
- 2945US2003118588A1Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40Filed 2002·Application pending·0 cites
- 3045US2010092435A1Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teippWIERTZ EMMANUEL JACQUES HENRI JOSEPH·Filed 2007·Application pending·0 cites
- 3141US2009220534A1Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopesUNIV LEIDEN MEDICAL CT·Filed 2007·Application pending·0 cites
- 3240US2022047603A1Substituted pyrrolopyridine-derivativesBAYER AG·Filed 2019·Application pending·0 cites
- 3337US2020246347A1Substituted Pyrrolopyridine-DerivativesBayer Pharma AG·Filed 2018·Application pending·0 cites
- 3434US2003186355A1Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopesFiled 2001·Application pending·0 cites
- 3533US2007025968A1Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopesSEED CAPITAL INVEST SCI B V·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →